Parmantier sets EUR 20.50 target for Evonik stock

Published on 10/15/2026 at 15:04 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Results are due November 3, 2026. Evonik stock costs EUR 20.84 on October 15, 2026, 1.42 percent below the Xetra close.

Analyst view and reporting date

Parmantier and Cie. set a EUR 20.50 target for Evonik on October 6, 2026.
Evonik reported EUR 3.89 billion in revenue for the second quarter of 2026.
Evonik stock costs EUR 20.84 at Lang & Schwarz on October 15, 2026 at 3:00 p.m. CEST, 1.42 percent below the Xetra close of October 14, 2026.
Evonik is scheduled to report third-quarter results on November 3, 2026.

Geometrisches Bauhaus-Poster mit fettem Text CHEMIE in Primärfarben Rot Gelb Blau nach 1920er Stil — Evonik Industries DE000EVNK013 als geometrisches Bauhaus-Poster mit dem Sektor-Text CHEMIE in leuchtenden Primärfarben, Illustration mit AI erstellt.

Parmantier & Cie. set a Hold rating and a EUR 20.50 six-month target for Evonik on October 6, 2026, according to EQS News. At EUR 20.84, the price lies 1.66 percent above that target. Evonik stock was trading at EUR 20.84 at Lang & Schwarz on October 15, 2026 at 3:00 p.m. CEST, down 1.42 percent versus the Xetra close of October 14, 2026.

What does the EUR 20.50 target imply?

The target sits below the Lang & Schwarz price, giving the analyst view a clear valuation counterpoint to the stock's recent level. The report's Hold rating reflects a six-month horizon and covers Evonik within a broader European chemicals study, rather than presenting a new company forecast.

Second-quarter figures set context

In the second quarter of 2026, Evonik generated EUR 3.89 billion in revenue and EUR 84.00 million in net income. Operating income was EUR 483.00 million, while operating cash flow reached EUR 204.00 million in the same period.

Price position and valuation

The stock's 52-week range is EUR 12.49 to EUR 21.84, putting the Lang & Schwarz price 4.58 percent below the high. The latest Xetra-linked quote data show a market capitalization of EUR 9.7 billion and a price-to-earnings ratio of 80.59 on October 15, 2026.

Dates and reporting schedule

Evonik's next scheduled reporting date is November 3, 2026, when the company will publish its third-quarter results, according to the company's investor-relations page. The date is the next hard checkpoint for comparing operating performance with the current analyst view.

Comparison with peers

Evonik (Xetra, EUR): minus 1.42 percent, P/E 80.59, market capitalization EUR 9.7 billion
Lanxess (Xetra, EUR): minus 0.72 percent, P/E minus 1.60, market capitalization EUR 1.1 billion
Wacker Chemie (Xetra, EUR): minus 2.05 percent, P/E minus 9.76, market capitalization EUR 4.3 billion

Evonik stock stays below its yearly high

The price remains EUR 1.00 below the 52-week high, while the analyst target is EUR 0.34 below the current quotation. The contrast places the stock between a high market valuation and a cautious six-month target.

The further course of trading is shown by the continuously updated real-time quote of Evonik stock.